EYE NEWS MEDIA

MEETING REPORTER: Rajen Desai, MD, FACS, discusses the challenges ophthalmologists face with patients with EDOF or premium lenses, particularly when they suffer from dry eyes and ocular surface toxicities due to postoperative drops like ketorolac and steroids. OMIDRIA® is presented as a solution that allows for reducing or eliminating these drops, resulting in quicker recovery and better vision clarity for patients. Rayner #ophthalmology #cataracts #escrs #ascrs #aao

MEETING REPORTER Tom Pace spoke with Shareef Mahdavi (author of Beyond Bedside Manner) at the #OUTLIERS MEETING in Nashville about the success of the meeting and how to transform your practice from ordinary to extraordinary! Uncover secrets to sustainable operations that go beyond clinical outcomes, with a focus on team excellence & profitability. Be an outlier! #outliermeeting, Robert F. I Melendez, MD, MBA,#ascrs #aao #escrs #ophthamologist

MEETING REPORTER: Dr. Carlton Fenzi discusses his 10-year experience with OMIDRIA® and highlights the significant differences in surgical outcomes between using OMIDRIA® and not using it.

MEETING REPORTER: Since 2007, the Rabb-Venable Excellence in Ophthalmology Program has been supported by NIH/NEI and led by course directors Dr. Mildred M.G. Olivier and Dr. Eydie Miller-Ellis.  Dr. Olivier says the Rabb-Venable Program is dedicated to cultivating culturally competent individuals who reflect the diverse population we serve. Our mission is anchored in the belief that a diversified medical field leads to improved patient health outcomes. By nurturing a community reflective of our patient demographics, we aim to enhance the overall healthcare experience.

MEETING REPORTER: I just returned from my first Outliers Meeting in Nashville—and now I understand why this event is gaining so much traction. Now in its fourth year, Outliers is unlike any other meeting I’ve attended. What stood out immediately was the focus on topics that often get overlooked at the larger conferences—things like: ✅ Enhancing the patient experience ✅ Integrating advanced technology in meaningful ways ✅ Driving profitability without compromising care These are real-world, practice-level conversations that make a difference—and they were front and center all weekend. What made it even better? Hearing directly from passionate, forward-thinking doctors and practice leaders who were generous with their insights and eager to share what’s working for them. Thanks to Robert F. I Melendez, MD, MBA and Josh for creating such a high-value experience for me. #ophthalmology

MEETING REPORTER AT AGS: Nathan Radcliffe, MD at the American Glaucoma Society 2025 meeting in Washington, DC, discusses the critical role of clinical data in glaucoma care. Dr. Radcliffe highlights the importance of clinical data in gaining 510(k) approval for procedures and their real-world effects on patients. He shares insights from a study on the OMNI® Surgical Device using the IRIS® database. The study tracked 200 patients over 36 months and demonstrated impressive intraocular pressure reduction and significant medication reduction, offering a promising standalone treatment for glaucoma patients. #ascrs #aao #escrs #glaucoma #eyedoc #eyesurgery

EYE NEWS MEETING REPORTER: Rebecca Metzinger, MD, explores the advantages of surgeon-delivered medications compared to the traditional three-in-one combination compounded drops for cataract surgery patients. Rayner #ascrs #aao #escrs #cataractsurgery #eyesurgeon

MEETING REPORTER at AGS 2025: Mona Athea Kaleem, MD, is transforming patient care one procedure at a time with the OMNI® Surgical System by Sight Sciences. From #canaloplasty to #goniotomy, it offers safety and durability across different disease stages, in combination with cataract surgery or standalone. #glaucoma #eyedoctor #ascrs #aao #escrs #cataracts

MEETING REPORTER: Steven R. Sarkisian, Jr., MD, talks about his paper at AGS 2025. We are witnessing a revolution in #glaucoma care! The transition towards eyedrop-free treatment is here, with excellent results from iDose® TR: Over 90% of patients are on the same or fewer meds after just one year! #glaucoma #aao #ascrs #aao #eyesurgeon

MEETING REPORTER AGS 2025: Nathan Radcliffe reports from AGS 2025 on a game-changing development in #glaucoma care – the Iantrek CycloPen™. Dr. Robert Weinreb presented data on a new study involving 51 patients with medically uncontrolled glaucoma. The study reported a 40% reduction in intraocular pressure (IOP) and a 41% reduction in medication use, maintained over 12 months. The biocompatible approach demonstrated excellent safety and efficacy, with impressive IOP reduction in refractory patients. The Iantrek CycloPen™ system has shown promising results through two years of data, providing an innovative interventional option for glaucoma patients, particularly those not yet ready for incisional surgeries. This early intervention can play a vital role in slowing disease progression and meeting the needs of approximately 2.5 million glaucoma patients. #aao #ascrs #escrs #glaucomasurgery #eyedoc #optomotry #ophthalmology #eyenewsmedia